Results 231 to 240 of about 85,022 (329)

The Real World Impact of Immunoglobulin Replacement Therapy on Severe Bacterial Infection for Patients With Hypogammaglobulinemia Secondary to Hematologic Malignancies: A Japanese Claims Database Study

open access: yeseJHaem, Volume 6, Issue 4, August 2025.
ABSTRACT Objectives The understanding of usefulness of immunoglobulin replacement therapy (IgRT) for hypogammaglobulinemia (HGG) in patients with hematologic malignancies (HM) has changed over time. This is mainly caused by the introduction of new treatment, such as B‐cell targeted agents.
Keichiro Mihara   +5 more
wiley   +1 more source

A rare case of precursor B-cell lymphoblastic lymphoma of the orbit in a child.

open access: yesOman J Ophthalmol
Jange RG   +5 more
europepmc   +1 more source

Mitochondria as Regulators of Nonapoptotic Cell Death in Cancer

open access: yesMedComm, Volume 6, Issue 8, August 2025.
Mitochondrial fission and fusion are key processes in maintaining cellular health. Fission is driven by proteins like, Fis‐1, which recruits DRP‐1, to facilitate the division of mitochondria. Fusion, however, is mediated by mitofusion 1(MFN1), mitofusion 2(MFN2), and optic atrophy 1 (OPA1), which work together to merge mitochondria, allowing functional
Saloni Malla   +8 more
wiley   +1 more source

Secondary neoplasms in survivors of pediatric acute lymphoblastic leukemia and lymphoblastic lymphoma: a single-center, retrospective study. [PDF]

open access: yesFront Pediatr
Ushida E   +12 more
europepmc   +1 more source

PI3K/AKT/mTOR Axis in Cancer: From Pathogenesis to Treatment

open access: yesMedComm, Volume 6, Issue 8, August 2025.
The PI3K/AKT/mTOR signaling axis is crucial in cancer progression, regulating cell growth, survival, and metabolism. Often hyperactivated through mutations or loss of tumor suppressors such as PTEN, this pathway promotes cancer cell proliferation and survival by inhibiting apoptosis and activating mTOR, which drives protein synthesis and suppresses ...
Mingyang Jiang   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy